JP6034309B2 - β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 - Google Patents

β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 Download PDF

Info

Publication number
JP6034309B2
JP6034309B2 JP2013554520A JP2013554520A JP6034309B2 JP 6034309 B2 JP6034309 B2 JP 6034309B2 JP 2013554520 A JP2013554520 A JP 2013554520A JP 2013554520 A JP2013554520 A JP 2013554520A JP 6034309 B2 JP6034309 B2 JP 6034309B2
Authority
JP
Japan
Prior art keywords
hmb
nutritional
methylbutyrate
hydroxy
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013554520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506890A5 (https=
JP2014506890A (ja
Inventor
ペドロサ，ホセ・マリア・ロペス
マルテイン，マヌエル・マンサーノ
ペレス，アレハンドロ・バランコ
ゴンザレス，マリア・ラミレス
カブレラ，リカルド・ルエダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2014506890A publication Critical patent/JP2014506890A/ja
Publication of JP2014506890A5 publication Critical patent/JP2014506890A5/ja
Application granted granted Critical
Publication of JP6034309B2 publication Critical patent/JP6034309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2013554520A 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法 Expired - Fee Related JP6034309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
US61/443,762 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016209276A Division JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Publications (3)

Publication Number Publication Date
JP2014506890A JP2014506890A (ja) 2014-03-20
JP2014506890A5 JP2014506890A5 (https=) 2015-03-26
JP6034309B2 true JP6034309B2 (ja) 2016-11-30

Family

ID=45757211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013554520A Expired - Fee Related JP6034309B2 (ja) 2011-02-17 2012-02-13 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016209276A Expired - Fee Related JP6340394B2 (ja) 2011-02-17 2016-10-26 β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法

Country Status (12)

Country Link
US (1) US9326956B2 (https=)
EP (1) EP2675298A1 (https=)
JP (2) JP6034309B2 (https=)
CN (1) CN103347406B (https=)
AR (1) AR085297A1 (https=)
BR (1) BR112013020643A2 (https=)
CA (1) CA2825734C (https=)
MX (1) MX348708B (https=)
PH (1) PH12013501671A1 (https=)
SG (1) SG192813A1 (https=)
TW (1) TWI565420B (https=)
WO (1) WO2012112419A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
BR112013020643A2 (pt) 2011-02-17 2016-08-02 Abbott Lab métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20150351438A1 (en) * 2013-01-29 2015-12-10 Otc Nutrition Llc Micronutrient Fortification Delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
EP2986162A1 (en) * 2013-03-15 2016-02-24 Abbott Laboratories Low calorie infant formula containing
WO2015148982A1 (en) * 2014-03-27 2015-10-01 Winterfield Roland W Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
ES2806684T3 (es) * 2015-09-16 2021-02-18 Abbott Lab Composición nutricional líquida, de larga duración y reducida en grasas
AU2016353003B2 (en) * 2015-11-10 2021-06-10 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) as an animal feed additive
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
JP5630750B2 (ja) 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
WO2010068696A1 (en) 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
BR112013016187A2 (pt) 2010-12-22 2018-07-10 Abbott Lab Produtos nutricionais compreendendo beta- hidróxi-beta metilbutirato de cálcio e ácido linoléico conjungado.
CN103269695A (zh) 2010-12-27 2013-08-28 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法
BR112013020643A2 (pt) 2011-02-17 2016-08-02 Abbott Lab métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
HK1205692A1 (en) 2012-03-19 2015-12-24 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
US20150238447A1 (en) 2012-09-17 2015-08-27 Abbott Laboratories Beta-hydroxy-beta-methylbutryic acid-containing compositions and uses thereof

Also Published As

Publication number Publication date
CN103347406B (zh) 2015-08-05
US20140249223A1 (en) 2014-09-04
CA2825734C (en) 2016-05-17
CN103347406A (zh) 2013-10-09
JP2017061483A (ja) 2017-03-30
JP6340394B2 (ja) 2018-06-06
SG192813A1 (en) 2013-09-30
EP2675298A1 (en) 2013-12-25
PH12013501671A1 (en) 2021-06-02
CA2825734A1 (en) 2012-08-23
MX348708B (es) 2017-06-26
US9326956B2 (en) 2016-05-03
JP2014506890A (ja) 2014-03-20
BR112013020643A2 (pt) 2016-08-02
TW201309212A (zh) 2013-03-01
TWI565420B (zh) 2017-01-11
WO2012112419A1 (en) 2012-08-23
AR085297A1 (es) 2013-09-18
WO2012112419A8 (en) 2014-03-06
MX2013009528A (es) 2013-10-01

Similar Documents

Publication Publication Date Title
JP6340394B2 (ja) β−ヒドロキシ−β−メチルブチラートを用いて脳の発達および認知機能を改善する方法
AU2017201766B2 (en) Method for treating neurotrauma
TWI407963B (zh) Contains the composition of riboflavin and sesamin
EP4162934A1 (en) Nutritional product
CN105682654A (zh) 用于改善认知功能的组合物和方法
TW201434470A (zh) 提昇認知功能及肌肉功能之營養組合物及方法
TW201524372A (zh) 用於提升認知能力的方法及組合物
US20020077349A1 (en) Method of treating age-related vision impairment
EP4353261A1 (en) Nutraceutic combination and its use in the treatment of neurological disorders
HK1240494A1 (en) Method for treating neurotrauma
HK1240494B (en) Method for treating neurotrauma
HK1195713B (en) Methods for increasing brain functionality using 2-fucosyl-lactose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160927

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161027

R150 Certificate of patent or registration of utility model

Ref document number: 6034309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees